ada standards of care 2025 glp-1 receptor agonists recommendations Update ✨ and GIP/GLP-1 Chart 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations

Contraindications CJC-1295 and Ipamorelin peptide therapy may not be suitable for individuals who: Have active or recent cancer Are pregnant or breastfeeding Are under the age of 18 Have uncontrolled blood sugar disorders A medical consultation is required to determine suitability prior to treatment

The MMNST may compress or invade the affected nerve, causing sensory or motor impairment in a corresponding area

However, anorexia, GI surgery and malabsorption, reduced intake of iodized supplements, and the area of origin (as soil levels of iodine are very low in mountainous regions) may represent risk factors for hypothyroidism

NORMAN SWAN: Well, there's no evidence on efficacy or safety